Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome
about
The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemiaEarly complications following haematopoietic SCT in children.Hepatopathy-thrombocytopenia syndrome (HTS) after actinomycin-D therapy: report of three cases and review of the literature.Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.Nutrient support in hematopoietic cell transplantation.Avoiding hepatic veno-occlusive disease: what do we know and where are we going?Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.Update on the use of defibrotide.A toxicologist's guide to biomarkers of hepatic response.Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplantRust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress.Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.Use of defibrotide in the treatment and prevention of veno-occlusive disease.How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation.Tusanqi-Related Sinusoidal Obstruction Syndrome in China: A Systematic Review of the Literatures.Novel Therapeutic Strategies in Acute Lymphoblastic Leukemia.High Incidence of Veno-Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (CCG-99702).Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation.Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and...Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation.High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT.Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide.High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma.Terminal hepatic venule injury in liver biopsies of allogeneic haematopoietic stem cell recipients-a study of 63 cases.Hepatic encephalopathy after treatment with temozolomide.Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failureTherapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
P2860
Q26783425-2CC6943E-1B44-40F0-BB3B-158DCA641074Q33379959-44F0A88D-1D6C-4D7D-A704-31018C627FA3Q33393867-A2583B90-3FF4-4925-A1F1-596AC713B769Q33915990-1A167086-3719-4D2C-9C66-78154D62A099Q33978951-A7002E15-1E55-4AC9-87EF-2B42631DB948Q34207695-44C29D25-A15D-41E9-9EAB-7C67A3A1129DQ34297653-66F84EE1-B695-4D1F-8917-68E819812965Q34364643-75A482FC-00F2-40D0-ADAC-AE8700FD478AQ34479575-16500429-8397-4CE7-B297-E30A782F4DACQ34635449-31073790-E9D1-4A26-AD5A-DC8693F1E641Q34761550-CFFD67F9-9A2A-48FB-B313-E35F092A74A6Q35626262-D77FDADC-BD75-40E8-B75D-3C394AA7B76FQ35787013-5E911A9C-5A82-4FFA-9FB8-E560535D9838Q35852267-7BC7AFB2-ADDA-4A4A-8CA1-73820153617CQ37073000-7151C5F1-A5E5-49A1-8306-06FAF095C5AFQ37810075-2D8ED144-089C-4B58-8D7D-9A2655A50D84Q38268712-A8B132DE-088F-46F2-A350-E629321FA889Q38523689-D9300D26-87F8-4678-A503-FCD036BA53CAQ38813978-06BDCE0D-0183-4B3B-B2D7-62600D2B6370Q40744398-F7AB2371-98F8-4981-AA62-BD9581C7F1F0Q43848079-19C06979-0EA4-4267-B333-27DB4CE61912Q43848120-C80F1E42-952C-499C-9A3E-C863CC7F2824Q44110270-BE7BEA2F-AA3D-4E08-86F5-33375A02871AQ45001844-F113E997-3E5D-47E7-8096-232F4A776DA6Q48239404-BFCC9A07-1490-47DC-9425-E7726006933AQ48349415-EAD5D57B-8E4B-4D7B-A373-6C6D729F5B11Q49276207-5EDC9CF0-A029-4B7F-9EBD-74F2D513BAC4Q49706246-8594BBDB-B9FE-41CD-B608-F3FCF729FD06Q52949564-A757A553-F77E-4EA2-9BAB-9B76B6CF3371Q53322702-2F5567F1-15F6-43A5-8B75-08278F3BE75EQ55463913-38C8DE35-67E8-405D-916E-3EE341A8F31CQ57301971-22A21FCB-A907-4A13-BA6A-F7B12E3AC306Q58789022-76785EC1-AFC2-4A5A-B93F-388415D206DD
P2860
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome
description
1999 nî lūn-bûn
@nan
1999 թուականին հրատարակուած գիտական յօդուած
@hyw
1999 թվականին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Veno-occlusive disease of the ...... nce, risk factors, and outcome
@ast
Veno-occlusive disease of the ...... nce, risk factors, and outcome
@en
Veno-occlusive disease of the ...... nce, risk factors, and outcome
@nl
type
label
Veno-occlusive disease of the ...... nce, risk factors, and outcome
@ast
Veno-occlusive disease of the ...... nce, risk factors, and outcome
@en
Veno-occlusive disease of the ...... nce, risk factors, and outcome
@nl
prefLabel
Veno-occlusive disease of the ...... nce, risk factors, and outcome
@ast
Veno-occlusive disease of the ...... nce, risk factors, and outcome
@en
Veno-occlusive disease of the ...... nce, risk factors, and outcome
@nl
P2093
P3181
P1476
Veno-occlusive disease of the ...... nce, risk factors, and outcome
@en
P2093
G B McDonald
K Schiffman
W Bensinger
P304
P3181
P356
10.1016/S1083-8791(99)70006-6
P407
P577
1999-01-01T00:00:00Z